S&P 500   3,275.65 (+1.20%)
DOW   27,071.71 (+1.15%)
QQQ   267.83 (+1.39%)
AAPL   109.72 (+2.43%)
MSFT   205.29 (+2.34%)
FB   250.24 (+0.49%)
GOOGL   1,428.30 (+1.34%)
AMZN   3,051.73 (+1.73%)
NVDA   500.83 (+3.27%)
TSLA   396.52 (+4.25%)
BABA   270.86 (-0.77%)
CGC   14.54 (-0.41%)
GE   6.15 (+0.65%)
MU   50.19 (+0.68%)
AMD   76.62 (+2.53%)
T   28.20 (+1.18%)
F   6.74 (+1.51%)
ACB   5.31 (+2.71%)
GILD   62.22 (-1.38%)
NFLX   473.88 (+0.69%)
DIS   123.66 (+0.31%)
BAC   23.73 (+2.02%)
BA   148.44 (-1.81%)
S&P 500   3,275.65 (+1.20%)
DOW   27,071.71 (+1.15%)
QQQ   267.83 (+1.39%)
AAPL   109.72 (+2.43%)
MSFT   205.29 (+2.34%)
FB   250.24 (+0.49%)
GOOGL   1,428.30 (+1.34%)
AMZN   3,051.73 (+1.73%)
NVDA   500.83 (+3.27%)
TSLA   396.52 (+4.25%)
BABA   270.86 (-0.77%)
CGC   14.54 (-0.41%)
GE   6.15 (+0.65%)
MU   50.19 (+0.68%)
AMD   76.62 (+2.53%)
T   28.20 (+1.18%)
F   6.74 (+1.51%)
ACB   5.31 (+2.71%)
GILD   62.22 (-1.38%)
NFLX   473.88 (+0.69%)
DIS   123.66 (+0.31%)
BAC   23.73 (+2.02%)
BA   148.44 (-1.81%)
S&P 500   3,275.65 (+1.20%)
DOW   27,071.71 (+1.15%)
QQQ   267.83 (+1.39%)
AAPL   109.72 (+2.43%)
MSFT   205.29 (+2.34%)
FB   250.24 (+0.49%)
GOOGL   1,428.30 (+1.34%)
AMZN   3,051.73 (+1.73%)
NVDA   500.83 (+3.27%)
TSLA   396.52 (+4.25%)
BABA   270.86 (-0.77%)
CGC   14.54 (-0.41%)
GE   6.15 (+0.65%)
MU   50.19 (+0.68%)
AMD   76.62 (+2.53%)
T   28.20 (+1.18%)
F   6.74 (+1.51%)
ACB   5.31 (+2.71%)
GILD   62.22 (-1.38%)
NFLX   473.88 (+0.69%)
DIS   123.66 (+0.31%)
BAC   23.73 (+2.02%)
BA   148.44 (-1.81%)
S&P 500   3,275.65 (+1.20%)
DOW   27,071.71 (+1.15%)
QQQ   267.83 (+1.39%)
AAPL   109.72 (+2.43%)
MSFT   205.29 (+2.34%)
FB   250.24 (+0.49%)
GOOGL   1,428.30 (+1.34%)
AMZN   3,051.73 (+1.73%)
NVDA   500.83 (+3.27%)
TSLA   396.52 (+4.25%)
BABA   270.86 (-0.77%)
CGC   14.54 (-0.41%)
GE   6.15 (+0.65%)
MU   50.19 (+0.68%)
AMD   76.62 (+2.53%)
T   28.20 (+1.18%)
F   6.74 (+1.51%)
ACB   5.31 (+2.71%)
GILD   62.22 (-1.38%)
NFLX   473.88 (+0.69%)
DIS   123.66 (+0.31%)
BAC   23.73 (+2.02%)
BA   148.44 (-1.81%)
Log in
NASDAQ:RGLS

Regulus Therapeutics Stock Forecast, Price & News

$0.46
-0.01 (-2.65 %)
(As of 09/24/2020 01:15 PM ET)
Add
Compare
Today's Range
$0.45
Now: $0.46
$0.48
50-Day Range
$0.45
MA: $0.59
$0.77
52-Week Range
$0.42
Now: $0.46
$1.74
Volume17,396 shs
Average Volume1.23 million shs
Market Capitalization$16.62 million
P/E RatioN/A
Dividend YieldN/A
Beta2
Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of medicines that target microRNAs to treat a range of diseases in the United States and Europe. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease. RGLS4326 is an anti-miR targeting miR-17 in Phase I clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug product candidates in renal, hepatic, and central nervous systems diseases. Regulus Therapeutics Inc. was founded in 2007 and is headquartered in San Diego, California.
Read More
Regulus Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.2Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.46 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:RGLS
CUSIP75915K10
Phone858-202-6300

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$6.83 million
Book Value$0.95 per share

Profitability

Net Income$-18,590,000.00
Net Margins-351.32%

Miscellaneous

Employees24
Market Cap$16.62 million
Next Earnings Date11/10/2020 (Estimated)
OptionableOptionable
$0.46
-0.01 (-2.65 %)
(As of 09/24/2020 01:15 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive RGLS News and Ratings via Email

Sign-up to receive the latest news and ratings for RGLS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Regulus Therapeutics (NASDAQ:RGLS) Frequently Asked Questions

How has Regulus Therapeutics' stock price been impacted by COVID-19 (Coronavirus)?

Regulus Therapeutics' stock was trading at $0.60 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, RGLS stock has decreased by 22.9% and is now trading at $0.4626.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Regulus Therapeutics?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Regulus Therapeutics in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Regulus Therapeutics
.

When is Regulus Therapeutics' next earnings date?

Regulus Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for Regulus Therapeutics
.

How were Regulus Therapeutics' earnings last quarter?

Regulus Therapeutics Inc (NASDAQ:RGLS) posted its quarterly earnings results on Thursday, August, 13th. The biopharmaceutical company reported ($0.23) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.11) by $0.13. Regulus Therapeutics had a negative net margin of 351.32% and a negative return on equity of 214.08%.
View Regulus Therapeutics' earnings history
.

What price target have analysts set for RGLS?

3 equities research analysts have issued 1 year price targets for Regulus Therapeutics' stock. Their forecasts range from $1.00 to $1.50. On average, they expect Regulus Therapeutics' share price to reach $1.25 in the next twelve months. This suggests a possible upside of 170.2% from the stock's current price.
View analysts' price targets for Regulus Therapeutics
.

Are investors shorting Regulus Therapeutics?

Regulus Therapeutics saw a decline in short interest during the month of August. As of August 31st, there was short interest totaling 1,150,000 shares, a decline of 27.7% from the August 15th total of 1,590,000 shares. Based on an average trading volume of 2,720,000 shares, the days-to-cover ratio is presently 0.4 days.
View Regulus Therapeutics' Short Interest
.

Who are some of Regulus Therapeutics' key competitors?

What other stocks do shareholders of Regulus Therapeutics own?

Who are Regulus Therapeutics' key executives?

Regulus Therapeutics' management team includes the following people:
  • Mr. Joseph P. Hagan, Pres, CEO & Director (Age 50)
  • Mr. Daniel R. Chevallard, Chief Financial Officer (Age 38)
  • Mr. Christopher Ray Aker J.D., VP of Legal Affairs & Corp. Sec.
  • Mr. Turner Jenkins, Director & Head of Corp. Devel.

What is Regulus Therapeutics' stock symbol?

Regulus Therapeutics trades on the NASDAQ under the ticker symbol "RGLS."

Who are Regulus Therapeutics' major shareholders?

Regulus Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include BVF Inc. IL (6.89%) and Virtu Financial LLC (0.40%). Company insiders that own Regulus Therapeutics stock include Christopher Ray Aker, Daniel R Chevallard, Joseph P Hagan, Kathryn J Collier, Pascale Witz, Peter J Barris and Stelios Papadopoulos.
View institutional ownership trends for Regulus Therapeutics
.

Which major investors are selling Regulus Therapeutics stock?

RGLS stock was sold by a variety of institutional investors in the last quarter, including BVF Inc. IL. Company insiders that have sold Regulus Therapeutics company stock in the last year include Christopher Ray Aker, and Joseph P Hagan.
View insider buying and selling activity for Regulus Therapeutics
.

Which major investors are buying Regulus Therapeutics stock?

RGLS stock was bought by a variety of institutional investors in the last quarter, including Virtu Financial LLC. Company insiders that have bought Regulus Therapeutics stock in the last two years include Joseph P Hagan, Kathryn J Collier, Pascale Witz, Peter J Barris, and Stelios Papadopoulos.
View insider buying and selling activity for Regulus Therapeutics
.

How do I buy shares of Regulus Therapeutics?

Shares of RGLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Regulus Therapeutics' stock price today?

One share of RGLS stock can currently be purchased for approximately $0.46.

How big of a company is Regulus Therapeutics?

Regulus Therapeutics has a market capitalization of $16.62 million and generates $6.83 million in revenue each year. The biopharmaceutical company earns $-18,590,000.00 in net income (profit) each year or ($1.08) on an earnings per share basis. Regulus Therapeutics employs 24 workers across the globe.

What is Regulus Therapeutics' official website?

The official website for Regulus Therapeutics is www.regulusrx.com.

How can I contact Regulus Therapeutics?

Regulus Therapeutics' mailing address is 10628 SCIENCE CENTER DRIVE SUITE 225, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 858-202-6300 or via email at [email protected]

This page was last updated on 9/24/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.